Dr. Raisz [1] states wittily that we are in the midst of an osteoporosis revolution. As an internist, I have to admit with shame that until recently I did not address this problem on a routine basis. Since I started screening patients for osteoporosis, I have identified about 10 to 15 osteoporotic patients a week. I have begun a crusade against osteoporosis in my primary care clinic. Nurses are required to measure the height of every patient older than 50 years of age, and a protocol to monitor patients receiving Fosamax (Merck & Co., Inc., Whitehouse Station, New Jersey) was introduced. I think that osteoporosis is one of the most common diseases in the primary care setting; unfortunately, it is also the most neglected. Raisz contributes to the osteoporosis battle but regrettably says that unlike heart disease and cancer, osteoporosis is not fatal. Osteoporosis is a potentially fatal disease, and sending this message to the health care policymakers is crucial. Osteoporosis not only affects quality of life but claims lives. In the United States, 250 000 hip fractures annually are attributable to osteoporosis, resulting in a 10% to 20% mortality rate over the subsequent 6 months [2]. This means that osteoporotic fractures pose a lifetime risk for death similar to that of breast cancer [3]. Merck & Co., Inc., uses these data to advertise Fosamax. We should use these dramatic statistics to convince health care policymakers to allocate funds to the treatment of osteoporosis. Medicare covers dual-energy x-ray absorptiometry measurements already. The next step is to get coverage for antiresorptive agents. Not many elderly osteoporotic patients can afford the $700 that a 1-year supply of Fosamax currently costs.